Abstract:

This study is a response to the challenge of malaria infections, which remain a major public health in South Africa. Reports of malarial outbreaks in the country have been predominant in KwaZulu-Natal, Mpumalanga, and Limpopo provinces. Currently, combination therapy referred to artemisinin-based combination treatments (ACTs) has been recommended both by the World Health Organization and the National Department of Health of South Africa. However, due to widespread reports of artemisinin resistance, other alternative treatment options were explored. The aim of the study was thus to establish the efficacy of plasmoquine as an alternative treatment option among malaria patients in Johannesburg, the economic capital of South Africa, found in the Gauteng Province. The study adopted a quantitative approach, and a purposive retrospective investigation was adopted. Patient data from 2018-2022 was analyzed to determine the incidence of malaria in the study location and the efficacy of treatment with plasmoquine. The results of this study, therefore, indicate that P. falciparum is still the main cause of malaria in the study area. A total of 322 patient files were included in the study, with P. falciparum determined to be the main cause of infection over the four-year data assessed. Furthermore, plasmoquine was determined to be effective in treating malaria among 298 of the study population, with only 24 (7.5%) experiencing the development of vomiting after the treatment course. The findings of the study offer government makes policymakers the opportunity to develop policies that enhance the re-introduction of plasmoquine to combat malaria in South Africa.

References:

[1] Domingues, W., Dos Santos, E. H., Yamamoto, L., Di Santi, S. M., Kanunfre, K. A., & Okay, T. S. (2022). Single-round multiplex PCR with species-specific mitochondrial primers of P. falciparum, P. vivax/P. simium and P. malariae/P. brasilianum: Comparison with standard techniques. Journal of Microbiological Methods, 193, 106398.

[2] Akilimali, A., Bisimwa, C., Aborode, A. T., Biamba, C., Sironge, L., Balume, A., ... & Fajemisin, E. A. (2022). Self-medication and Anti-malarial Drug Resistance in the Democratic Republic of the Congo (DRC): A silent threat. Tropical Medicine and Health, 50(1), 1-5.

[3] Weiss, D. J., Bertozzi-Villa, A., Rumisha, S. F., Amratia, P., Arambepola, R., Battle, K. E., & Gething, P. W. (2021). Indirect effects of the Covid-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis. The Lancet Infectious Diseases, 21(1), 59-69.

[4] Macharia, P. M., Giorgi, E., Noor, A. M., Waqo, E., Kiptui, R., Okiro, E. A., & Snow, R. W. (2018). Spatio-temporal analysis of Plasmodium falciparum prevalence to understand the past and chart the future of malaria control in Kenya. Malaria journal, 17(1), 1-13.

[5] White, N. J. (2019). Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance. Malaria journal, 18(1), 1-3.

[6] Carman (1935)

[7] Gilles HM. Management of severe malaria: a practical handbook. 2nd Edition. Geneva: World Health Organization, 2000.

[8] van der Pluijm, R. W., Amaratunga, C., Dhorda, M., & Dondorp, A. M. (2021). Triple artemisinin-based combination therapies for malaria–a new paradigm? Trends in parasitology, 37(1), 15-24.

[9] Wicht, K. J., Small-Saunders, J. L., Hagenah, L. M., Mok, S., & Fidock, D. A. (2022). Mutant PfCRT Can Mediate Piperaquine Resistance in African Plasmodium falciparum With Reduced Fitness and Increased Susceptibility to Other Antimalarials. The Journal of Infectious Diseases.

[10] McLean, A. R., Indrasuta, C., Khant, Z. S., Phyo, A. K., Maung, S. M., Heaton, J., ... & Smithuis, F. M. (2021). Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. The Lancet Infectious Diseases, 21(11), 1579-1589.

[11] Naing, C., Whittaker, M. A., Htet, N. H., Aye, S. N., & Mak, J. W. (2019). Efficacy of anti-malarial drugs for treatment of uncomplicated falciparum malaria in Asian region: A network meta-analysis. Plos one, 14(12), e0225882.

[12] Njau, J., Silal, S. P., Kollipara, A., Fox, K., Balawanth, R., Yuen, A., ... & Moonasar, D. (2021). Investment case for malaria elimination in South Africa: a financing model for resource mobilization to accelerate regional malaria elimination. Malaria journal, 20(1), 1-16.

[13] Martineau, P., Behera, S., Nonaka, M., Jayanthi, R., Ikeda, T., Minakawa, N., ... & Mabunda, Q. (2022). Predicting malaria outbreaks from sea surface temperature variability up to 9 months ahead in Limpopo, South Africa, using machine learning. Frontiers in public health, 10.

[14] Craig et al. (2004), Malaria Research Programme, Medical Research Council, Durban, South Africa

[15] Raman, J., Morris, N., Frean, J., Brooke, B., Blumberg, L., Kruger, P., ... & Moonasar, D. (2016). Reviewing South Africa’s malaria elimination strategy (2012–2018): progress, challenges, and priorities. Malaria journal, 15(1), 1-11.

[16] Cui, L., Yan, G., Sattabongkot, J., Cao, Y., Chen, B., Chen, X.s & Zhou, G. (2012). Malaria in the Greater Mekong Subregion: heterogeneity and complexity. Acta tropica, 121(3), 227-239

[17] Nosten, F., & White, N. J. (2007). Artemisinin-based combination treatment of falciparum malaria. Defining and Defeating the Intolerable Burden of Malaria III: Progress and Perspectives: Supplement to Volume 77 (6) of American Journal of Tropical Medicine and Hygiene.

[18] World Health Organization. (2016). Eliminating malaria in the Greater Mekong Subregion: United to end a deadly disease (No. WHO/HTM/GMP/2016.12). World Health Organization.

[19] National Department of Health: Pretoria: South African National Department of Health. 2019. Malaria elimination strategic plan for South Africa 2019-2023.

[20] World Health Organization: Geneva: World Health Organization; 2017. A framework for malaria elimination.